NCCN now recognizes BCG-unresponsive papillary-only NMIBC as eligible for nogapendekin plus BCG, broadening access beyond the ...

ImmunityBio (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the successful completion of manufacturing engineering programs, NK2022 and NK2023, establishing a safe, ...

CD19 CAR NK cell therapy, alone or with rituximab, shows promise in relapsed/refractory B-cell NHL, including Waldenström macroglobulinemia. Two heavily pretreated WM patients achieved complete ...

Adoptive cell therapy (ACT) has emerged as a transformative approach in cancer immunotherapy, with remarkable clinical success in hematological ...

Controversy exists as to the role that the immune system plays in cancer therapy. While the immune system has been proposed to scavenge the body to prevent microscopic transformation from forming ...

Enhanced quantity and functionality of natural killer (NK) cells in hepatocellular carcinoma (HCC) have been associated with improved prognosis and survival. Therefore, NK cell-based immunotherapy has ...

A phase 1 clinical trial co-led by researchers at WashU Medicine found that a new type of cell-based immunotherapy was safe for patients with several types of B-cell lymphoma, a type of blood cancer.

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with the potential to overcome key limitations of current chimeric antigen ...

R3 Stem Cell is offering highest grade immunotherapy with Natural Killer Cells in Tijuana Mexico. The immunotherapy works well for several cancer treatments. The goal with NK Cell immunotherapy for ...